中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

2609 records (took 0.029 seconds)

    METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT
    6.
    发明申请
    METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT 审中-公开

    公开(公告)号：WO2022236364A1

    公开(公告)日：2022-11-17

    申请号：PCT/AU2022/050437

    申请日：2022-05-10

    Applicant: TOPELIA AUST LIMITED (ACN 652 771 670)

    Inventor： BORODY, Thomas Julius ,  DOLAI, Sibasish

    IPC: A61K31/00 ,  A61K39/12 ,  A61K39/02 ,  A61K39/002 ,  G01N33/569 ,  A61K31/53 ,  A61P31/00 ,  A61K35/76 ,  G01N2469/20 ,  G01N33/54366

    Abstract: In alternative embodiments, provided are methods for treating, ameliorating, decreasing the chances of having any adverse effects from, decreasing the severity of adverse effects from, or preventing an infection, or boosting or enhancing natural immunity acquired by an infected individual, by administration of: an inactivated infectious causative agent of the infection, or an antibiotic and/or an anti-viral drugs and a vaccine directed to a causative agent of the infection and/or an attenuated and/or a live, viable or infectious causative agent of the infection. In alternative embodiments, the infection is bacterial or viral. In alternative embodiments, the viral infection is a coronavirus infection such a Covid-19 infection. In alternative embodiments, methods as provide herein prevent or decrease the prevalence or severity of "vaccine breakthrough infections" after vaccination, where external mutants of COVID-19 infect patients in spite of the fact that they have undergone immunization, for example, to prevent a mutant or variant COVID-19 infection. In alternative embodiments, an antiviral combination administered in coordination with a vaccine comprises PF-07321332 or PAXLOVID™ and/or ritonavir, or ivermectin, doxycycline and a zinc or a zinc salt. In alternative embodiments, methods as provided herein are used to prevent in vivo mutations of such mutant infectious agent to enhance the efficacy of an administered vaccination; in other words, methods as provided herein are used to prevent in vivo replication of an acquired viral mutant or variant infectious agent, and thus also prevents ongoing mutations of the viral infectious agent because using the combination antiviral co-therapy where there is no replication of infectious agent and so there is no possible further mutation of the infectious agent.

    ADENOVIRUS FOR TREATMENT OF CANCER
    8.
    发明申请
    ADENOVIRUS FOR TREATMENT OF CANCER 审中-公开

    公开(公告)号：WO2022225441A1

    公开(公告)日：2022-10-27

    申请号：PCT/SE2022/050389

    申请日：2022-04-21

    Applicant: ELICERA THERAPEUTICS AB

    Inventor： YU, Di

    IPC: C12N15/861 ,  A61K35/761 ,  A61K48/00 ,  A61K39/02 ,  C07K14/205 ,  A61P35/00 ,  C07K14/705

    Abstract: The invention relates to an adenovirus comprising a nucleic acid sequence encoding a Helicobacter pylori neutrophil-activating protein (NAP) and/or a nucleic acid sequence encoding an immunologically equivalent fragment of NAP and a nucleic acid sequence encoding an immunomodulator capable of inducing an immune response in a subject. The adenovirus has enhanced clinical effects in terms of delaying tumor growth and prolonging survival.

Patent Agency Ranking